US Patent

US8846695 — Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2030-06-04 · 4y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of using a DPP-IV inhibitor to improve glycemic control in type 2 diabetes patients who are not responding to metformin therapy.

USPTO Abstract

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1503 — Tradjenta
U-1503 — Tradjenta
U-1503 — Tradjenta
U-1503 — Tradjenta

Patent Metadata

Patent number
US8846695
Jurisdiction
US
Classification
Method of Use
Expires
2030-06-04
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.